ABSTRACT
Glioblastoma, the most common primary brain malignancy, is invariably fatal. Systemic chemotherapy is ineffective mostly because of drug delivery limitations. To overcome this, we devised an internalized pump-catheter system for direct chronic convection-enhanced delivery (CED) into peritumoral brain tissue. Topotecan (TPT) by chronic CED in 5 patients with refractory glioblastoma selectively eliminated tumor cells without toxicity to normal brain. Large, stable drug distribution volumes were non-invasively monitored with MRI of co-infused gadolinium. Analysis of multiple radiographically localized biopsies taken before and after treatment showed a decreased proliferative tumor signature resulting in a shift to a slow-cycling mesenchymal/astrocytic-like population. Tumor microenvironment analysis showed an inflammatory response and preservation of neurons. This novel drug delivery strategy and innovative clinical trial paradigm overcomes current limitations in delivery and treatment response assessment as shown here for glioblastoma and is potentially applicable for other anti-glioma agents as well as other CNS diseases.
Competing Interest Statement
JNB has a consulting agreement with Theracle, Inc. JNB held the Sponsor-Investigator IND for this study.
Clinical Trial
NCT03154996
Funding Statement
This research was funded in part by NIH/NCI R01CA161404 (JNB) and NIH/NINDS R01NS103473 (PC, PAS, JNB), Also funded in part through the NIH/NCI Cancer Center Support Grant P30CA013696 as well as the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873. ABL was supported in part by grants 5P30CA013696-43 and 5UG1CA189960-04 from the NCI. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB (protocol # AAAQ9520) of Columbia University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This research was funded in part by NIH/NCI R01CA161404 (JNB) and NIH/NINDS R01NS103473 (PC, PAS, JNB), Also funded in part through the NIH/NCI Cancer Center Support Grant P30CA013696 as well as the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873. ABL was supported in part by grants 5P30CA013696-43 and 5UG1CA189960-04 from the NCI. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Disclosure Statement: JNB has a consulting agreement with Theracle, Inc. The Sponsor-Investigator IND for this study was held by JNB.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
